We don't have a Bears article about Pfizer (PFE)/Wyeth (WYE) yet.

You could be the first person to write a bearish analysis about Pfizer (PFE)/Wyeth (WYE). As the first editor, you could earn a "Top Contributor" spot if you have an account.

Top 3 Bears Arguments

Wyeth has suffered several regulatory delays on key drugs which throw doubt on the health of its pipeline.

Wyeth is currently facing thousands of cases relating to withdrawn diet and hormone therapy drugs. This huge liability has weighed on the stock and has adversely impacted the company's cash flow.

Although Wyeth has a broad array of drugs in its pipeline, it has limited success in producing highly anticipated drugs highly with blockbuster potential.

Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki